Beta Bionics, Inc. (BBNX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$17.42-9.88%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Beta Bionics aims to fully commercialize its Mint product by mid-2027. Revenue guidance for 2026 was raised to about $133.5 million. Gross margin is expected to improve to about 58.5%. The company has delivered multiple recent earnings beats.
The company remains unprofitable with negative EPS expected through 2027. FDA regulatory risks and a recent warning letter pose challenges. Revenue growth and margin improvements may fall short of targets.
The stock price is about 49% above our fair value estimate near $12. Analysts expect roughly 40% revenue growth. Our view aligns with these growth expectations but notes ongoing losses and regulatory risks.
Breaks if: Gross margin falls below 57.5% in 2026
Increase gross margin to a range of 58.5% to 59.5% for full year 2026, reflecting operational efficiencies and product mix improvements.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
BBNX represents a speculative growth investment with a focus on future commercialization and revenue growth. The current thesis state indicates a cautious watch due to weak recent performance compared to peers.
The market appears to expect a durable premium for BBNX, though there is a slight expectations gap suggesting that current performance may not fully align with investor hopes. Valuation is considered justified, indicating that the market does not see significant fragility at this time.
Management is on track with revenue guidance and gross margin improvements, but the overall financial performance remains weak. There is a medium confidence level in the company's ability to execute on its priorities, with some risks present in the near term.
Key factors include the company's ability to commercialize its product Mint by mid-2027 and the impact of broader sector performance on BBNX. Additionally, any negative shifts in economic indicators, such as job reports, could adversely affect the company.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings report showed a positive surprise. This beat indicates better-than-expected performance, which supports a more favorable outlook for BBNX. There are no new threats identified that could weaken this view.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 quarters including 2025-Q4 through 2026-Q2. Gross margin guidance improved from 55.5%-57.5% to 58.5%-59.5% for 2026. Actual gross margin rose from 50.9% in 2025-Q1 to 59.5% in 2026-Q1 and was 59.0% in 2026-Q2, showing delivery on margin improvement goals.
“Gross margin of 59.0%, up 524 basis points compared to 53.8% in second quarter 2025.”
“Gross margin of 59.5%, up 864 basis points compared to 50.9% in first quarter 2025.”
“Estimated gross margin of 57.5% to 59.5% for 2026, improved from 55.5% to 57.5%.”
Breaks if: Mint commercialization delayed beyond 2027-Q2
Breaks if: 2026 revenue falls below $131 million
Raise full year 2026 revenue guidance to approximately $131 million to $136 million, reflecting growth in net sales and channel expansion.
Stated as a priority in 3 consecutive quarters from 2025-Q4 through 2026-Q2. Revenue guidance increased from $130-$135 million to $131-$136 million for 2026. Actual net sales grew from $40.9 million in first half 2025 to $59.6 million in first half 2026, reflecting growth consistent with raised guidance, indicating delivery on this priority.
“Estimated total revenue of approximately $131 million to $136 million (no change versus previous guidance).”
“Raised full year 2026 revenue guidance to approximately $131 million to $136 million (previously $130 million to $135 million).”
“Introduced annual guidance for 2026 with estimated total revenue of approximately $130 million to $135 million.”
Over the next 1 to 3 years, BBNX's performance will depend heavily on its execution against stated priorities and external economic conditions. Not investment advice.